Literature DB >> 9467533

Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.

G Van den Berghe1, F de Zegher, R C Baxter, J D Veldhuis, P Wouters, M Schetz, C Verwaest, E Van der Vorst, P Lauwers, R Bouillon, C Y Bowers.   

Abstract

The catabolic state of prolonged critical illness is associated with a low activity of the thyrotropic and the somatotropic axes. The neuroendocrine component in the pathogenesis of these low activity states was assessed by investigating the effects of continuous intravenous infusions of TRH, GH-releasing peptide-2 (GHRP-2), and GHRH. Twenty adult patients, critically ill for several weeks, were studied during two consecutive nights. They had been randomly allocated to one of three combinations of peptide infusions, each administered in random order: TRH (one night) and placebo (other night), TRH + GHRP-2 (one night) and GHRP-2 (other night), or TRH + GHRH + GHRP-2 (one night) and GHRH + GHRP-2 (other night). The peptide infusions were started after a 1-microgram/kg bolus and infused (1 microgram/kg per h) until 0600 h. Blood sampling was performed every 20 min, and pituitary hormone secretion was quantified by deconvolution analysis. Reduced pulsatile fraction of TSH, GH, and PRL secretion and low serum concentrations of T4, T3, insulin growth factor-I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were documented in the untreated state. Infusion of TRH alone or in combination with GH secretagogues augmented nonpulsatile TSH release 2- to 5-fold; only TRH + GHRP-2 increased pulsatile TSH secretion (4-fold). Average rises in T4 (40-54%) and in T3 (52-116%) were obtained with all three combinations, whereas reverse T3 levels did not increase, except when TRH was infused alone. Pulsatile GH secretion was amplified > 6- and > 10-fold, respectively, by GHRP-2 and GHRH + GHRP-2 infusions, generating mean increases of serum IGF-I (66% and 106%), IGFBP-3 (50% and 56%), and ALS (65% and 97%) within 45 h. The addition of TRH did not alter the GH secretory patterns. TRH infusion increased PRL release only when combined with GH secretagogues. No effects on serum cortisol were detected. In conclusion, the pathogenesis of the low activity state of the thyrotropic and somatotropic axes in prolonged critical illness appears to have a neuroendocrine component, because these axes are both readily activated by coinfusion of TRH and GH secretagogues.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467533     DOI: 10.1210/jcem.83.2.4575

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

1.  The dilemma of non-thyroidal illness syndrome: to treat or not to treat?

Authors:  L Bartalena
Journal:  J Endocrinol Invest       Date:  2003-12       Impact factor: 4.256

Review 2.  "Non-thyroidal illness syndrome" is functional central hypothyroidism, and if severe, hormone replacement is appropriate in light of present knowledge.

Authors:  L J DeGroot
Journal:  J Endocrinol Invest       Date:  2003-12       Impact factor: 4.256

3.  Low triiodothyronine syndrome: a prognostic marker for outcome in sepsis?

Authors:  Stefanie Meyer; Philipp Schuetz; Melanie Wieland; Charly Nusbaumer; Beat Mueller; Mirjam Christ-Crain
Journal:  Endocrine       Date:  2011-01-06       Impact factor: 3.633

Review 4.  Pituitary function during severe and life-threatening illnesses.

Authors:  C Gauna; G H van den Berghe; A J van der Lely
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 5.  Growth hormone secretagogues as diagnostic tools in disease states.

Authors:  R Baldelli; X L Otero; J P Camiña; O Gualillo; V Popovic; C Dieguez; F F Casanueva
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

6.  Effects of substitution and high-dose thyroid hormone therapy on deiodination, sulfoconjugation, and tissue thyroid hormone levels in prolonged critically ill rabbits.

Authors:  Yves Debaveye; Björn Ellger; Liese Mebis; Theo J Visser; Veerle M Darras; Greet Van den Berghe
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

7.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

8.  Non-Thyroidal Illness Syndrome in Critically Ill Children: Prognostic Value and Impact of Nutritional Management.

Authors:  An Jacobs; Inge Derese; Sarah Vander Perre; Esther van Puffelen; Sören Verstraete; Lies Pauwels; Sascha Verbruggen; Pieter Wouters; Lies Langouche; Gonzalo Garcia Guerra; Koen Joosten; Ilse Vanhorebeek; Greet Van den Berghe
Journal:  Thyroid       Date:  2019-03-11       Impact factor: 6.568

Review 9.  Nonthyroidal illness syndrome in children.

Authors:  Seth D Marks
Journal:  Endocrine       Date:  2009-09-25       Impact factor: 3.633

10.  Changes in the central component of the hypothalamus-pituitary-thyroid axis in a rabbit model of prolonged critical illness.

Authors:  Liese Mebis; Yves Debaveye; Björn Ellger; Sarah Derde; Eric-Jan Ververs; Lies Langouche; Veerle M Darras; Eric Fliers; Theo J Visser; Greet Van den Berghe
Journal:  Crit Care       Date:  2009-09-11       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.